Physician

Latha Sree Polavaram, MD

According to 2025 Medicare claims, Latha Polavaram, MD (NPI: 1194934802) practices hematology/oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49503-2563. Polavaram is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Polavaram's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 234 traditional Medicare patients, billed 22,602 HCPCS/CPT codes, and received $491,338 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,129 prescription claims across 221 beneficiaries totaling $4,600,094 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 12 claims. Open Payments data shows 17 records totaling $63,899. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,401,416 to $4,600,094. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,826 to $862.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	580	82,017	$1,368,420
2016	499	110,394	$1,625,592
2017	578	96,819	$1,679,492
2018	611	96,349	$2,303,975
2019	449	69,546	$1,461,349
2020	428	90,327	$1,756,080
2021	472	103,154	$1,856,265
2022	479	93,612	$1,389,277
2023	463	97,962	$1,262,441
2024	234	22,602	$491,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	339	1,706	$1,401,416
2016	323	1,783	$2,156,093
2017	348	2,088	$4,055,733
2018	338	2,116	$5,513,676
2019	264	2,095	$6,498,866
2020	250	2,517	$8,107,782
2021	274	2,762	$10,724,606
2022	278	2,691	$12,277,974
2023	273	2,540	$9,953,484
2024	221	1,129	$4,600,094

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	102	$27,496
2016	N/R	43	$3,564
2017	N/R	46	$8,280
2018	N/R	49	$1,443
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$813
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	172	727	$10
82784	Gammaglobulin (immune system protein) measurement	61	553	$9
36415	Insertion of needle into vein for collection of blood sample	179	951	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	183	976	$8
83615	Lactate dehydrogenase (enzyme) level	157	396	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	73	2,002	$1,269,126
Lenalidomide	Lenalidomide	56	1,554	$802,551
Pomalyst	Pomalidomide	19	532	$435,138
Calquence	Acalabrutinib Maleate	30	900	$434,056
Imbruvica	Ibrutinib	25	708	$299,113

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	16	$417	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$63,482	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Latha Sree Polavaram, MD?

Tedicare shows public-source Medicare data for Latha Sree Polavaram, MD (NPI 1194934802), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Latha Sree Polavaram, MD have ACO affiliation data?

Latha Sree Polavaram, MD is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Latha Sree Polavaram, MD?

Latha Sree Polavaram, MD is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Latha Sree Polavaram, MD have Open Payments data?

Latha Sree Polavaram, MD has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.